Main Article Content

Muhammad Zaini Fahmi
Hidayah Karuniawati
Wan Ismahanisa Ismail

Page: 1916-1922

Abstract

Chronic Obstructive Pulmonary Disease (COPD) is one of the leading causes of global morbidity and mortality, with a continuously increasing health burden. The complexity of long-term therapy in COPD increases the risk of Drug-Related Problems (DRPs), which can affect patient clinical outcomes. This literature review was conducted descriptively by searching articles in the PubMed, Scopus, Google Scholar, and ScienceDirect databases using keywords related to DRPs and COPD. The selection was made on publications from the last 10 years (2015–2025) relevant to the topic and available in full text. Based on studies by Li et al., (2019) and Apikoglu-Rabus et al., (2016), the classification of DRPs according to PCNE V9.0 mainly included aspects of medication safety (54.2%), inappropriate drug selection (up to 8.7%), excessive dosage (19.9%), excessive duration of therapy (17.7%), and errors in the drug use process (up to 63.3%). Patient factors such as non-compliance (25%) and incorrect inhalation techniques were the main contributors to the occurrence of DRPs. Inappropriate use of medications, drug-herb interactions, and lack of therapy monitoring were also consistently found. The findings suggest that DRPs significantly worsen symptom control and increase the risk of exacerbations. Pharmacists are critical in identifying, preventing, and managing DRPs through patient education, therapy review, and ongoing therapy monitoring. DRPs in COPD patients are a serious challenge that requires a multidisciplinary approach. Ongoing education, monitoring of therapy rationality, and collaboration between healthcare professionals are needed to improve patient safety and the effectiveness of COPD treatment.

Downloads

Download data is not yet available.

Article Details

How to Cite
Fahmi, M. Z., Karuniawati, H., & Ismail, W. I. (2025). Drug-Related Problems in Chronic Obstructive Pulmonary Disease: Literature Review. Journal of Pharmaceutical and Sciences, 8(3), 1916–1922. https://doi.org/10.36490/journal-jps.com.v8i3.955
Section
Review Article

References

Aprilen N, Indratama IMB. Profile of chronic obstructive pulmonary disease (COPD) patients in Oksibil Regional Public Hospital in 2020. J Penyakit Dalam Udayana 2022;6:10–4. https://doi.org/10.36216/jpd.v6i1.179. DOI: https://doi.org/10.36216/jpd.v6i1.179

Firdausi NL, Artanti KD, Li C-Y. Analysis of Risk Factors Affecting The Occurrence of Chronic Obstructive Pulmonary Disease in Indonesia. J Berk Epidemiol 2021;9:18. https://doi.org/10.20473/jbe.v9i12021.18-25. DOI: https://doi.org/10.20473/jbe.V9I12021.18-25

Chen S, Kuhn M, Prettner K, Yu F, Yang T, Bärnighausen T, et al. The global economic burden of chronic obstructive pulmonary disease for 204 countries and territories in 2020–50: a health-augmented macroeconomic modelling study. Lancet Glob Heal 2023;11:e1183–93. https://doi.org/10.1016/S2214-109X(23)00217-6. DOI: https://doi.org/10.1016/S2214-109X(23)00217-6

PDPI. Guidelines For Diagnosis And Management of COPD In Indonesia. 2023rd ed. Indonesia: 2023. https://doi.org/10.1002/9783527809080.cataz12474. DOI: https://doi.org/10.1002/9783527809080.cataz12474

Barnes PJ. Inflammatory mechanisms in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol 2016;138:16–27. https://doi.org/10.1016/j.jaci.2016.05.011. DOI: https://doi.org/10.1016/j.jaci.2016.05.011

Pham HQ, Pham KHT, Ha GH, Pham TT, Nguyen HT, Nguyen THT, et al. Economic Burden of Chronic Obstructive Pulmonary Disease: A Systematic Review. Tuberc Respir Dis (Seoul) 2024;87:234–51. https://doi.org/10.4046/trd.2023.0100. DOI: https://doi.org/10.4046/trd.2023.0100

Apikoglu-Rabus S, Yesilyaprak G, Izzettin FV. Drug-related problems and pharmacist interventions in a cohort of patients with asthma and chronic obstructive pulmonary disease. Respir Med 2016;120:109–15. https://doi.org/10.1016/j.rmed.2016.10.006. DOI: https://doi.org/10.1016/j.rmed.2016.10.006

Hudd TR. Emerging role of pharmacists in managing patients with chronic obstructive pulmonary disease. Am J Heal Pharm 2020;77:1625–30. https://doi.org/10.1093/ajhp/zxaa216. DOI: https://doi.org/10.1093/ajhp/zxaa216

Wu P, Jiang YQ, Si FL, Wang HY, Song XB, Sheng CF, et al. Pharmaceutical treatment status of patients with COPD in the community-based on the medical Internet of Things: a real-world study. Npj Prim Care Respir Med 2024;34. https://doi.org/10.1038/s41533-024-00371-0. DOI: https://doi.org/10.1038/s41533-024-00371-0

Ahmed NA, Fouad EA, El-Asheer OM, Ghanem ASM. Pharmaceutical interventions for drug-related problems in the neonatal intensive care unit: incidence, types, and acceptability. Front Pharmacol 2024;15:1–14. https://doi.org/10.3389/fphar.2024.1391657. DOI: https://doi.org/10.3389/fphar.2024.1391657

Pharmaceutical Care Network Europe Association. PCNE Classification for Drug-Related Problems V9.1. PCNE Assoc 2020;1:22–8.

Schindler E, Richling I, Rose O. Pharmaceutical Care Network Europe (PCNE) drug-related problem classification version 9.00: German translation and validation. Int J Clin Pharm 2021;43:726–30. https://doi.org/10.1007/s11096-020-01150-w. DOI: https://doi.org/10.1007/s11096-020-01150-w

Li Q, Qu HJ, Lv D, Yeh MK, Sun S, Li L, et al. Drug-related problems among hospitalized patients with COPD in mainland China. Int J Clin Pharm 2019;41:1507–15. https://doi.org/10.1007/s11096-019-00913-4.

Li Q, Qu HJ, Lv D, Yeh MK, Sun S, Li L, et al. Drug-related problems among hospitalized patients with COPD in mainland China. Int J Clin Pharm 2019;41:1507–15. https://doi.org/10.1007/s11096-019-00913-4. DOI: https://doi.org/10.1007/s11096-019-00913-4

Dong YH, Hsu CL, Li YY, Chang CH, Lai MS. Use of Bronchodilators in patients with COPD. Int J COPD 2015;10:1769–79. https://doi.org/10.2147/COPD.S86198. DOI: https://doi.org/10.2147/COPD.S86198

Duan R, Li B, Yang T. Pharmacological therapy for stable chronic obstructive pulmonary disease. Chronic Dis Transl Med 2023;9:82–9. https://doi.org/10.1002/cdt3.65. DOI: https://doi.org/10.1002/cdt3.65

Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease Report 2020. Glob Initiat Chronic Obstr Lung Dis 2020:141.

Funakoshi H, Momo K, Okazaki K, Ebato T, Yamamoto S, Uno T, et al. β2-adrenoceptor agonist inhalation induced paroxysmal atrial fibrillation and tachycardia in a patient with severe bronchial asthma. Br J Clin Pharmacol 2021;87:3375–7. https://doi.org/10.1111/bcp.14741. DOI: https://doi.org/10.1111/bcp.14741

Rodrigo GJ, Price D, Anzueto A, Singh D, Altman P, Bader G, et al. LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: A systematic review and meta-analysis. Int J COPD 2017;12:907–22. https://doi.org/10.2147/COPD.S130482. DOI: https://doi.org/10.2147/COPD.S130482

Adisa R, Ufuah UF, Ige OM. Impact of pharmacist-led intervention in medication adherence and inhaler usage on asthma and chronic obstructive pulmonary disease control: a quasi-experimental study. BMC Health Serv Res 2024;24:1199. https://doi.org/10.1186/s12913-024-11683-9. DOI: https://doi.org/10.1186/s12913-024-11683-9

Putcha N, Wise RA. Medication regimens for managing COPD exacerbations. Respir Care 2018;63:773–82. https://doi.org/10.4187/respcare.05912. DOI: https://doi.org/10.4187/respcare.05912

Rodrigues AT, Romano S, Romão M, Figueira D, Bulhosa C, Madeira A, et al. Effectiveness of a pharmacist-led intervention on inhalation technique for asthma and COPD patients: The INSPIRA pilot cluster-randomized controlled trial. Respir Med 2021;185. https://doi.org/10.1016/j.rmed.2021.106507. DOI: https://doi.org/10.1016/j.rmed.2021.106507